Our findings constitute evidence justifying further studies of the frequency of MET germline mutations in high-risk populations, the role of MET inhibitors in cancer prevention, and the use of MET-T1010I as biomarker for inclusion of patients in therapeutic studies of MET inhibitors. This evidence concerns the gene MET and cancer.